Abstract：
Antiamyloid therapies for Alzheimer disease recently entered clinical practice, making imaging biomarkers for Alzheimer disease even more relevant to guiding patient management. Amyloid and tau PET are valuable tools that can provide objective evidence of Alzheimer pathophysiology in living patients and will increasingly be used to complement 18F-FDG PET in the diagnostic evaluation of cognitive impairment and dementia. Parkinsonian syndromes, also common causes of dementia, can likewise be evaluated with a PET imaging biomarker,18F-DOPA, allowing in vivo assessment of the presynaptic dopaminergic neurons. Understanding the role of these PET biomarkers will help the nuclear medicine physician contribute to the appropriate diagnosis and management of patients with cognitive impairment and dementia. To successfully evaluate brain PET examinations for neurodegenerative diseases, knowledge of the necessary protocol details for obtaining a reliable imaging study, inherent limitations for each PET radiopharmaceutical, and pitfalls in image interpretation is critical. This review will focus on underlying concepts for interpreting PET examinations, important procedural details, and guidance for avoiding potential interpretive pitfalls for amyloid, tau, and dopaminergic PET examinations.
摘要：
抗淀粉样蛋白治疗阿尔茨海默病最近进入临床实践，使阿尔茨海默病的成像生物标志物与指导患者管理更加相关。淀粉样蛋白和tauPET是有价值的工具，可以为活着的患者提供阿尔茨海默病病理生理学的客观证据，并且将越来越多地用于补充18F-FDGPET，用于认知障碍和痴呆的诊断评估。帕金森综合征,也是痴呆症的常见原因，同样可以用PET成像生物标志物进行评估，18F-DOPA,允许体内评估突触前多巴胺能神经元。了解这些PET生物标志物的作用将有助于核医学医师为认知障碍和痴呆症患者的适当诊断和管理做出贡献。为了成功评估神经退行性疾病的脑PET检查，了解必要的协议细节，以获得可靠的成像研究，每种PET放射性药物的固有局限性，图像解释中的陷阱至关重要。这篇综述将侧重于解释PET检查的基本概念，重要的程序细节，以及避免淀粉样蛋白潜在解释陷阱的指导，tau,和多巴胺能PET检查。
